Lixte Biotechnology Holdings, Inc. announced that in preclinical studies its lead clinical compound, LB-100, a protein phosphatase (PP2A) inhibitor, was found to increase the responsiveness of diverse cancers to immunotherapy. In Nature Communications (15 Dec 2021), lead author Yu-Ting Yen and colleagues at the China Medical University and Hospital, Taichung, Taiwan reported that treatment with LB-100 is associated with new antigen production, tumor infiltration of cytotoxic T cells, and enhanced responsiveness to immune checkpoint blockade in mouse models of colorectal, triple-negative breast, and pancreatic cancer.